INTRODUCTION
In platelets, elevation in cytosolic [Ca 2+ ] i is imperative to almost all functional responses. Moderate and transient rises in [Ca 2+ ] i mediate shape change, integrin α IIb β 3 activation, thromboxane formation and secretion of granule contents, while high and prolonged [Ca 2+ ] i rises are required for the procoagulant response (1, 2) . The latter is achieved by a Ca 2+ -activated scramblase mechanism disturbing the normal phospholipid asymmetry in the plasma membrane, with as a result the exposure of phosphatidylserine (PS) 2 at the outer membrane surface (3, 4) . Exposed PS provides high-affinity binding sites for key coagulation factors and, thereby, facilitates the assembly of tenase and prothrombinase complexes, which are responsible for the formation of factor Xa and thrombin, respectively (3) . Since thrombin is one of the most potent platelet agonists, the procoagulant platelet response triggers a potent positive feedback loop of platelet and coagulation activation. Recent in vivo studies have indicated that PS exposure and ensuing thrombin generation are key regulatory events in murine arterial thrombus formation (5, 6) .
Whereas stored platelets may expose procoagulant PS in a Ca 2+ -independent way, PS exposure in activated platelets relies on a high and prolonged rise in cytosolic [Ca 2+ ] i (7) . Platelet stimulation with single G-proteincoupled agonists, like thrombin and ADP, results in limited PS exposure (8, 9) , but stimulation of the tyrosine kinase-linked collagen receptor glycoprotein VI (GPVI), with ligands such as collagen-related peptide (CRP) or convulxin, results in appreciable procoagulant activity (10, 11) . Combined stimulation of the collagen and thrombin receptors though results in high PS exposure, likely because these agonists use different signaling pathways for mobilizing cytosolic Ca 2+ (1) . While thrombin transiently activates Gqα and phospholipase Cβ2/β3 isoforms, activation of GPVI causes a more persistent activation of the phospholipase Cγ2 isoform (2, 12) . For PS exposure, entry of extracellular Ca 2+ is required, complementing the Ca 2+ -mobilizing effect of phospholipase C stimulation, in order to reach sufficiently high [Ca 2+ ] i (10, 13, 14) . In platelets like other cells, Ca 2+ entry can be triggered by receptor stimulation as well as by Ca 2+ mobilization from stores via the processes of receptor-operated Ca 2+ entry (ROCE) and store-operated Ca 2+ entry (SOCE), respectively (15) . For long, not only the responsible Ca 2+ entry channels, but also the coupling mechanisms of receptor activation and Ca 2+ store depletion to channel opening have remained elusive. In earlier work with platelets, roles of the TRPC1 and TRPC6 channel proteins in Ca 2+ entry have been proposed (16, 17) . Recent studies however have shown the importance of the Orai class of plasma membrane Ca 2+ channels. The channel Orai1 (also called CRACM1) oligomerizes and opens, following depletion of the Ca 2+ stores, by interacting with Ca 2+ sensing stromal-interacting molecule 1 (STIM1), which is a transmembrane protein located in the endoplasmic reticulum (18) (19) (20) . The homologous protein STIM2 can have a similar regulatory role in Ca 2+ entry (21) . Both Orai1 and STIM1 have been implicated in the physiological activation of T cells and mast cells (22, 23) . Recent studies using genetically modified mice have established that STIM1 and Orai1 account for the large majority of SOCE in platelets. The importance of this SOCE pathway appeared from the finding that platelet deficiency in either Orai1 or STIM1 protects against collagen-dependent arterial thrombus formation and brain infarction in vivo (24, 25) . In confirmation, others have provided evidence that a functional R93W mutation in Orai1 leads to impaired GPVI-induced platelet activation (26) .
In the present paper, we investigated whether the STIM isoforms and Orai1 provide the main Ca 2+ entry mechanism responsible for PS exposure and procoagulant activity in platelets stimulated by the collagen and thrombin receptors. The studies were carried out using mice with Stim1
-/-platelets.
EXPERIMENTAL PROCEDURES
Mouse Strains-Animal studies were approved by the local animal care and use committees. Mice homozygously deficient in Stim1 or Orai1 were generated from embryonic stem cell clones and germline transmission, as described (24, 25) . Since these animals suffered from early lethality and growth retardation, bone marrow chimeras were created which had normal viability. Female, 5-6 weeks old C57BL/6 mice were irradiated with a single dose of 10 Gy, and injected intravenously with bone marrow cells from donor Stim1
Orai1
-/-or wild type mice (4 × 10 6 cells/animal). The recipient mice received acidified water containing 2 g/l neomycin sulfate for 6 weeks after transplantation. Blood was taken from the chimeras after >6 weeks. Mice homozygously deficient in Stim2 had a mixed genetic background and were compared with wild types of the same background (27) . Blood cell counts of all mice were in the normal range. Purified platelets from (bone marrowtransplanted) mice were subjected to Western blotting to confirm knockout of STIM proteins. Deficiency in Orai1 transcripts was confirmed by RT-PCR analysis (25) .
Materials-H-Phe-Pro-Arg chloromethyl ketone (PPACK) was obtained from Calbiochem. Annexin A5 labeled with fluorescein isothiocyanate (FITC), Fura-2 and Fluo-4 acetoxymethyl esters and pluronic F-127 were from Invitrogen. Thrombin substrate, Z-Gly-GlyArg aminomethyl coumarin (Z-GGR-AMC), was from Bachem; fibrillar type I collagen (Horm) from Nycomed; recombinant human tissue factor from Dade Behring. Apyrase (grade V), bovine serum albumin (BSA), heparin, SKF96365 and thrombin were from Sigma. The GPVI agonist, CRP was synthesized and cross-linked by Tana Laboratories; the agonist convulxin was purified as described (11) . FITC-labeled anti-mouse Pselectin mAb was from Emfret Analytics. Bovine coagulation factors and other materials were from sources indicated before (28).
Blood Collection and Platelet PreparationMouse blood was obtained via orbital puncture under anesthesia. For perfusion studies in the absence of coagulation, blood was collected into a mixture of 40 µM PPACK, 5 U/ml heparin and 40 U/ml fragmin. For later perfusions with coagulation, blood was collected into 12.9 mM trisodium citrate. Citrate-anticoagulated blood was also used to prepare platelet-rich plasma (PRP), normalized with autologous platelet-poor plasma (PPP) to a platelet count of 1 × 10 8 /ml. Washed platelets were prepared from PRP by supplementation of ACD solution (1:25) . After centrifugation, platelets were suspended in Hepes buffer pH 7.45 (136 mM NaCl, 5 mM Hepes, 2.7 mM KCl, 2 mM MgCl 2 , 0.42 mM Na 2 HPO 4 , 5 mM glucose and 0.1% BSA). Cells were counted with a Coulter counter.
Activation of Suspended Platelets-Washed mouse platelets were loaded with the ratiometric Ca 2+ probe, Fura-2, as described (24) . Platelets suspended in the presence or absence of 1 mM CaCl 2 were preincubated with SKF96365 (100 µM), and activated with collagen and/or thrombin receptor agonists, as indicated. Changes in fluorescence was measured with a PerkinElmer LS 55 fluorometer. Excitation was alternated between 340 and 380 nm, and emission was measured at 509 nm. Calibration parameters of nanomolar [Ca 2+ ] i were obtained by lysis with 1% Triton X-100 and addition of a surplus of EGTA. For flow cytometry, unloaded washed platelets (1 × 10 8 /ml) were activated in the presence of CaCl 2 with indicated agonists for 10 min; stirring was absent to prevent platelet aggregation (29) . Surface expression of PS was detected in the presence of CaCl 2 (2 mM) with FITC-annexin A5 (0.5 µg/ml).
Thrombus Formation on Collagen-Glass coverslips were coated with fibrillar type I collagen and blocked with BSA-containing Hepes buffer pH 7.45. The coverslips were mounted in a transparent, 50 µm-deep parallelplate poly(methyl) methacrylate flow chamber (30) . Mouse blood was perfused through the flow device at defined shear rate under physiological, millimolar concentrations of divalent cations. For experiments in the absence of coagulation, PPACK/heparin-treated blood was flowed over collagen at 1000 s -1 during 4 min. For experiments in the presence of coagulation, citrate-anticoagulated blood was recalcified directly before entering the flow chamber, using a two-pump system (29) . Briefly, 1 ml syringes were filled with citrate-anticoagulated blood or isotonic CaCl 2 /MgCl 2 solution (110 mM NaCl, 13.3 mM CaCl 2 and 6.7 mM MgCl 2 ). The syringes were connected to the flow chamber via a v-shaped inlet, designed to give optimal fluid mixing. By co-infusing both fluids into the chamber at equal flow rate (final shear rate, 1000 s -1 ), coagulation was started by collagen-and factor XII-dependent activation (31) . The thrombi on coverslips were post-labeled by perfusion with FITC-annexin A5 (0.5 µg/ml) in Hepes buffer pH 7.45, containing 2 mM CaCl 2 and 1 U/ml heparin. Brightfield and fluorescence images were recorded from at least 10 randomly chosen microscopic fields (32) . Images were analyzed with ImagePro software (Media Cybernetics). The procoagulant index of thrombi was determined as the ratio of surface coverage of PS-exposing platelets (FITC-annexin A5) to the coverage of total platelets (33) .
Single Platelet Ca 2+ Fluxes under FlowMouse platelets were loaded with Fluo-4 (34), and added to PPACK/fragmin-or citrateanticoagulated blood from the same genotype (10% labeled platelets). During blood flow over collagen, 16-bit digital fluorescence images were recorded at high-speed (5 Hz) using an EM-CCD camera (31) . Regions-of-interest representing single adhered platelets were analyzed off-line for changes in fluorescence (F) (34) . Pseudoratio F/F o values were converted into nanomolar concentrations of [Ca 2+ ] i using predefined calibration parameters (35) . For quantitative purposes, traces from individual cells were superimposed, so that [Ca 2+ ] i rises started at the same frame number.
Prothrombinase Activity-Prothrombinasestimulating activity was determined at linear assay conditions, as previously assessed for human platelets (36) . Washed mouse platelets were diluted in Hepes buffer pH 7.45 containing 3 mM CaCl 2 to a count of 4 × 10 5 /ml, and incubated with 0.5 µM prothrombin, 2 nM factor Va and 1 nM factor Xa (37 °C). Samples were taken after exactly 3 min, and transferred to vials containing thrombin substrate, S2238 (0.5 mM), for chromogenic measurement of the thrombin formed.
Thrombin Generation-Thrombin generation was measured in citrate-anticoagulated PRP (28). The PRP, pooled from 3 animals with the same (chimeric) genotype, was diluted with autologous PPP to a count of 1.5 × 10 8 platelets/ml. Samples were activated with convulxin (100 ng/ml), ionomycin (20 µM) or vehicle for 15 min. Aliquots (4 vol.) were then transferred to a polystyrene 96-wells plate (Immulon 2HB, Dynex Technologies), already containing 1 vol. of buffer A (20 mM Hepes, 140 mM NaCl, 0.5% BSA and 6 pM tissue factor). Coagulation was started by adding 1 vol. of buffer B (2.5 mM Z-GGR-AMC, 20 mM Hepes, 140 mM NaCl, 100 mM CaCl 2 and 6% BSA). First-derivative curves were converted into nanomolar thrombin concentrations using a calibrator for human α-thrombin (28). All analyses were in duplicate.
Statistics-Differences between groups were tested for significance with the non-parametric Mann-Whitney U test. Paired data were compared with a Student t test. The statistical package for social sciences (SPSS 15.0) was used.
RESULTS

Deficiency in Platelet STIM1 or Orai1
Impedes GPVI-mediated PS Exposure and Thrombus Formation-For the experiments, chimeric mice were generated by transplantation of irradiated wild type animals with Stim1
Orai1
-/-or wild type bone marrow cells. Platelets from these mice, isolated at least 4 weeks after transplantation, were checked for absence of STIM1 protein or Orai1 transcript (supplemental Fig. 1A, B) . The platelets from chimeric Stim1
-/-mice were greatly impaired in Ca 2+ rises evoked by the GPVI agonist, CRP (a triple helical collagen peptide), or by thrombin, most markedly when extracellular CaCl 2 was present (supplemental Fig. 1C ), which is in full agreement with earlier data (24, 25) . In addition, Stim1 -/-platelets showed reduced Ca 2+ rises in the absence of CaCl 2 and Ca 2+ entry, supporting the concept that STIM1 controls the filling state of Ca 2+ stores (24) . Blood from these chimeric mice was anticoagulated with PPACK/heparin, and perfused at high-shear flow rate over a collagen surface. By using these thrombin inhibitors, blood coagulation was ablated, while high, physiological concentrations of free Ca 2+ and Mg 2+ were maintained. In this test of collageninduced thrombus formation, platelets in contact with the collagen fibers become activated via GPVI, and respond by Ca 2+ elevation, PS exposure and secretion of autocrine mediators, with as a result platelet aggregate formation (5, 33, 37) . Strikingly, with blood from chimeric Stim1 -/-and Orai1 -/-mice, no or only small aggregates were formed, while PS exposure was almost completely absent, as apparent from the lack of staining with FITC-labeled annexin A5 (Fig. 1A) . This contrasted to the large aggregates and many PS-exposing platelets observed with blood from corresponding wild type mice.
Analysis of microscopic images pointed to a markedly reduced deposition of Stim1
-/-(-70%) and Orai1 -/-(-46%) platelets in comparison to wild type. The procoagulant index, i.e. the relative formation of PS-exposing platelets compared to all adhered platelets (33) , was also greatly reduced in either knockout (Fig. 1B) .
Mouse platelets were loaded with Fluo-4 and back-added to blood of the same genotype in order to measure Ca 2+ rises in the cells during blood flow over collagen. Wild type platelets showed high Ca 2+ responses shortly after adhesion ( Fig. 2A) (29) . To determine the role of STIM1 and Orai1 in this setting, citrate-anticoagulated blood from chimeric animals was co-infused with CaCl 2 /MgCl 2 to achieve again millimolar free Ca 2+ and Mg 2+ concentrations. Perfusion of the recalcified blood over collagen leads to onset of coagulation via collagen-dependent activation of factor XII (31) . With wild type blood, massive and dense thrombi (clots) were formed within 4 min of perfusion, which were covered with PSexposing platelets and connected by fibrin fibers (Fig. 3A) . Surprisingly, dense fibrin-containing thrombi were also formed with (Fig. 4A ), which were higher in level than those measured in anti-coagulated blood (Fig. 2B) . With the thrombin inhibitor hirudin present, the mean Ca 2+ rises reduced from about 400 to 250 nM, which confirmed the contribution of thrombin to the Ca 2+ signal. Interestingly, in recalcified blood, also collagenadhered Stim1
-/-and Orai1 -/-platelets showed prolonged Ca 2+ responses, but these remained lower in magnitude than those of wild type platelets (Fig. 4B) . The effect of STIM1 knockout was again more pronounced than that of Orai1 deficiency. Hence, under these conditions of in situ formation of thrombin, platelet Ca 2+ responses seem to be sufficiently high for PS exposure even in the absence of the STIM1-Orai1 SOCE pathway.
Deficiency in STIM1 or Orai1 Does not Affect GPVI-Induced PS Exposure and Prothrombinase
Activity with Thrombin Present-To investigate this further, washed platelets were stimulated with collagen (GPVI)-and/or thrombin-receptor agonist, and staining of the cells was observed with the PS probe, FITC-annexin A5. Extracellular CaCl 2 was present to allow Ca 2+ entry. The GPVI agonist convulxin was used for these studies (12) , which is similarly effective as CRP in wild type and Orai1-deficient platelets (25) . Flow cytometric analysis showed that convulxin stimulation of wild type platelets resulted in about 20% PS-exposing platelets (Fig.  5A ). This fraction increased to 73% with thrombin as co-agonist, whereas thrombin alone had no more than little effect. Stimulation of platelets from chimeric Stim1 -/-and Orai1 -/-mice with convulxin resulted in impaired PS exposure, comparable to stimulation with thrombin alone. However, combined stimulation with convulxin and thrombin resulted in 53-58% PS positive platelets, which was similar to that of wild type platelets. Control experiments indicated that all platelets responded nearly completely, when stimulated with the Ca 2+ ionophore, ionomycin. As an alternative approach, we studied the capacity of platelets to support prothrombinase activity, i.e., the PS-dependent cleavage of prothrombin by factors Xa and Va (13 (Fig. 6A) . In all groups, pre-stimulation with ionomycin caused a 3-4 fold increase in thrombin generation, indicating that the knockout platelets were normally capable to support thrombin generation (Fig. 6B) . Pre-stimulation with convulxin resulted in a significant increase in thrombin peak height in all groups, but in this case STIM1-or Orai1-deficient PRP was less effective than wild type PRP in comparison to pre-stimulation with ionomycin. The time-topeak was less shortened in convulxin-stimulated knockout PRP in comparison to wild type (Fig.  6C) . Taken together, these results show that, in the presence of thrombin (either externally added or formed in situ), GPVI-dependent PS exposure and procoagulant activity are only partly affected by deficiency in platelet STIM1 or Orai1.
Roles of Ca 2+ Entry Channels Other than Orai1-The modest roles of STIM1 and Orai1 in GPVI-dependent platelet procoagulant activity in the presence of thrombin suggests the presence of a compensating Ca 2+ entry mechanism, that for instance could be triggered in a receptoroperated fashion. In other cell types, it has been shown that also STIM2 regulates Ca 2+ entry by controlling cytoplasmic Ca 2+ levels (38) . Since mouse platelets highly express this isoform (supplemental Fig. 1B) , we studied the possibility that STIM2-mediated Ca 2+ regulation controls the extent of PS exposure. Mice homozygously deficient in STIM2 are viable and have normal platelet counts (27) . Stimulation of Fura-2-loaded Stim2 -/-platelets showed unaltered Ca 2+ responses upon stimulation of GPVI (Fig.  7A, B) or thrombin-receptors (not shown). Flow perfusion experiments over collagen, performed with blood from the Stim2 -/-mice, indicated the formation of large thrombi and the presence of many PS exposing platelets (Fig. 7C) . Furthermore, detailed image analysis pointed to an unchanged procoagulant index of Stim2 -/-thrombi in comparison to Stim2 +/+ thrombi (Fig. 7D ). The putative role of other Ca 2+ entry channels was investigated by using the established Ca 2+ entry blocker, SKF96365 (39) . To compare with earlier established Ca 2+ traces (supplemental Fig.  1 ), Fura-2-loaded platelets were activated with GPVI agonist CRP, thrombin or the combination of both. In wild type platelets, pretreatment with SKF96365 inhibited the Ca 2+ responses to all agonists with 60-70%, only if CaCl 2 was present in the incubation medium (Fig. 8A) . On the other hand, when no CaCl 2 was added and Ca 2+ entry was prevented, SKF96365 did not have a significant effect (Fig. 8B) (Fig. 8A) .
Further experiments demonstrated that the SKF96365-inhibitable Ca 2+ entry pathway was important for procoagulant activity, as it suppressed the GPVI/thrombin-mediated PS exposure in both wild type (-73 ± 8%) and Orai1 -/-platelets (-34 ± 6%, p < 0.05). Together, these data point to the involvement of a second Ca 2+ entry pathway in platelet PS exposure that is different from the Orai1 channels.
DISCUSSION
This study examines the contribution of recently discovered Ca 2+ entry pathways to the regulation of platelet procoagulant activity and thrombus formation. A first key finding is that deficiency in the Ca 2+ sensor STIM1 or the Ca 2+ -selective channel Orai1 greatly reduces GPVIdependent PS exposure and thrombus formation under conditions of flow and absence of coagulation. This corresponds to a major reduction in the Ca 2+ responses of collagenadhered Stim1
-/-and Orai1 -/-platelets. Thus, it can be concluded that the reduced GPVI-induced Ca 2+ signaling leads to impaired PS exposure and platelet aggregation. Interestingly, platelets from Stim2 -/-mice are normally active in thrombus formation and PS exposure under the same flow conditions, indicating that the STIM2 homologue is not implicated in these platelet responses.
Detailed single cell analysis yet points to discernible differences between the genotypes, in that a sub-population of the collagen-adhered Orai1 -/-platelets, but not of the Stim1 -/-platelets, displays residual spiking in Ca 2+ . This residual Ca 2+ signal will be a consequence of the appreciable GPVI-induced Ca 2+ mobilization from internal stores of Orai1-deficient platelet (25) , such in contrast to the markedly reduced Ca 2+ store mobilization of STIM1-deficient platelets (24) . This difference between the genotypes was confirmed in CRP-and thrombininduced activation studies with Fura-2-loaded platelets. The present findings agree with the recent evidence that a dysfunctional R93W mutation of the Orai1 channel leads to partial impairment of GPVI-induced PS exposure (26) . Collectively, our data underline the importance of both SOCE regulating proteins in sheardependent platelet activation by collagen under conditions where the contribution of thrombin is absent or limited.
The second key finding is that, under conditions of flow and coagulation, deficiency in platelet STIM1 or Orai1 does not abolish the capability to PS exposure and formation of a fibrin-containing thrombus. Under these conditions, collagen-adhered Stim1 -/-and Orai1 -/-and Orai1 -/-platelets, implying that the STIM1-Orai1 interaction forms the principal SOCE mechanism (24, 25) . A similar conclusion has been drawn for other secretory cells, e.g. T cells and mast cells (41) . However, it now appears that both Stim1 -/-and Orai1 -/-platelets show significant Ca 2+ responses and PS exposure, when co-stimulated via GPVI and thrombin receptors. This is suggestive for the presence of another, compensatory mechanism of Ca 2+ entry, acting in a (thrombin) receptoroperated fashion.
This hypothesis is supported by our finding that the imidazole antagonist SKF96365, which is a well-studied inhibitor of Ca 2+ entry in platelets (39) , is still capable to suppress the Ca 2+ and procoagulant responses of platelets deficient in STIM1 or Orai1. Unfortunately, this compound can not be used in measurements of thrombus formation, since it rapidly inactivates in the presence of blood plasma (data not shown). In Fura-2-loaded Stim1 -/-and Orai1 -/-platelets, SKF96365 still inhibits 40-60% of the Ca 2+ signal independently of the agonist (GPVI ligand and/or thrombin). The slow, non-Orai1 Ca 2+ entry most likely does not involve the TRPC1 channel (16), since Trpc1 -/-platelets have a fully intact Ca 2+ signaling machinery (42) . Other candidate target proteins of SKF96365 are the non-SOCE channels, TRPC6 and Orai3, both of which act in a receptor-operated way, and are expressed in platelets (17, 19) . Further studies are required to identify this channel.
A pending question is whether the SOCE mechanism per se is implicated in the transmembrane scrambling of phospholipids, which is the underlying event of PS exposure. Such a role of SOCE has been proposed by others (43) . However, the current findings do not support this, since Stim1 -/-and Orai1 -/-platelets (both devoid of SOCE) almost normally expose PS upon combined collagen-and thrombinreceptor stimulation. This is in agreement with the finding that platelets from Scott syndrome patients, which have a defect in PS exposure, show unchanged Ca 2+ signals in response to collagen/thrombin (44) . Together, this strongly argues against a role of SOCE or other Ca 2+ channels as phospholipid scramblase proteins.
The present findings support the idea that the Orai1 channel is an attractive target for pharmacological treatment of thrombosis. Previous results have demonstrated that the deficiency of Orai1 in mouse platelets protects from arterial thrombus formation, particularly in thrombosis models that are collagen-dependent (24, 25) . Since collagen-independent thrombosis models mostly rely on tissue factor exposure and thrombin generation (6) , it is plausible that specific targeting of Orai1 (or STIM1) restricts platelet procoagulant activity and thrombus formation only under conditions, where the role of tissue factor is limited. Hence, targeting of Orai1 may be more effective to prevent thrombosis in arteries, where (tissue factordependent) thrombin accumulation is confined by the high-shear flow conditions. In contrast, blockage of Orai1 may not impair bleeding from wounds where tissue factor is abundantly exposed. Indeed, mice deficient in Orai1 have only a mild prolongation of the tail bleeding time (25) . Whether inhibition of the non-Orai1 (non-SOCE) channels targeted by SKF96365 also provides antithrombotic protection, still needs to be investigated. 
